Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
First-in-Human Study of Novel Oral Dual-Acting Antibody in Development for Treatment of Patients with Inflammatory Bowel Disease SALT LAKE CITY, UT, UNITED STATES, November 1, 2023 /EINPresswire.com/ — Sorriso Pharmaceuticals, a biopharmaceutical company developing novel oral antibodies in immune-mediated disease, today announced that the first subject has been dosed in the company’s Phase 1/1b clinical […]